- CEO
- Junya Suzuki
- Full Time Employees
- 5,305
- Sector
- Commercial services
- Industry
- Commercial printing/Forms
- Address
- 3 Mibu Hanai-cho Kyoto KY Japan 604-8551
- IPO Date
- Oct 1, 1961
- Business
- Nissha Co., Ltd. manufactures and sells industrial materials, devices, medical technologies, and related products utilizing core technologies in printing, coating, molding, and metal processing. The company operates through segments including Industrial Materials, offering decorative film-molded parts such as in-mold decoration, in-mold labeling, in-mold electronics, transfer foil, injection molding, metallized paper and board, and sustainable molded products like PaperFoam; Devices, providing touch sensors, force sensors, gas sensors including hydrogen and refrigerant detectors, film heaters, film antennas, and related components; Medical Technologies, encompassing design and manufacturing of single-use medical devices, patient monitoring consumables, disposable ECG electrodes, medical cables, wearables, and minimally invasive surgical devices; as well as Pharmaceuticals and Quasi-drugs, featuring contract development and manufacturing of film-type pharmaceuticals such as oral thin films, transdermal patches, and dissolving microneedle patches, alongside own-brand offerings and services like Re&Go takeout container sharing; Information and Communication, including publication printing, commercial printing, high-definition digital archives, fabric printing, and business media such as industrial recording and ticket/card materials. Nissha maintains a global footprint with operations in Japan, North and South America, Europe, and Asia, including subsidiaries like Nissha USA, Inc., Nissha Medical Technologies, Nissha Europe GmbH, Nissha (Kunshan) Precision IMD Mold Co., Ltd., and Nissha Vietnam Co., Ltd., serving markets in automotive interiors, consumer electronics, healthcare, and pharmaceuticals. Founded in 1929 and headquartered in Kyoto, Japan, the company lists on the Tokyo Stock Exchange Prime Market (7915.T) and employs approximately 5,455 consolidated staff as of June 2025. Recent developments include the acquisition of SHIGAKEN PHARM. IND. CO., LTD., completed in early 2025, marking entry into pharmaceutical contract development and manufacturing organization services for over-the-counter drugs like cold medicines and analgesics across diverse dosage forms and packaging; relocation of engineering operations to Nashville, Tennessee, creating 38 jobs and investing $4.5 million; and a 2023 partnership with Restech to double production of Stretta catheters.